bluebird bio Statistics
Total Valuation
bluebird bio has a market cap or net worth of $81.18 million. The enterprise value is $385.63 million.
Important Dates
The last earnings date was Thursday, November 14, 2024, before market open.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
bluebird bio has 9.72 million shares outstanding. The number of shares has increased by 72.23% in one year.
| Current Share Class | 9.72M |
| Shares Outstanding | 9.72M |
| Shares Change (YoY) | +72.23% |
| Shares Change (QoQ) | +0.09% |
| Owned by Insiders (%) | 0.49% |
| Owned by Institutions (%) | 38.00% |
| Float | 9.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.37 |
| Forward PS | 0.44 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.26 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.51
| Current Ratio | 0.51 |
| Quick Ratio | 0.29 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.24 |
Financial Efficiency
Return on equity (ROE) is -270.20% and return on invested capital (ROIC) is -44.45%.
| Return on Equity (ROE) | -270.20% |
| Return on Assets (ROA) | -36.91% |
| Return on Capital (ROIC) | -44.45% |
| Revenue Per Employee | $141,653 |
| Profits Per Employee | -$780,867 |
| Employee Count | 375 |
| Asset Turnover | 0.10 |
| Inventory Turnover | 2.10 |
Taxes
| Income Tax | -83,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -70.80% in the last 52 weeks. The beta is 0.73, so bluebird bio's price volatility has been lower than the market average.
| Beta (5Y) | 0.73 |
| 52-Week Price Change | -70.80% |
| 50-Day Moving Average | 8.15 |
| 200-Day Moving Average | 14.66 |
| Relative Strength Index (RSI) | 49.22 |
| Average Volume (20 Days) | 327,998 |
Short Selling Information
The latest short interest is 2.41 million, so 24.83% of the outstanding shares have been sold short.
| Short Interest | 2.41M |
| Short Previous Month | 2.58M |
| Short % of Shares Out | 24.83% |
| Short % of Float | 24.95% |
| Short Ratio (days to cover) | 9.53 |
Income Statement
In the last 12 months, bluebird bio had revenue of $53.12 million and -$292.83 million in losses. Loss per share was -$33.56.
| Revenue | 53.12M |
| Gross Profit | -25.66M |
| Operating Income | -318.48M |
| Pretax Income | -91.14M |
| Net Income | -292.83M |
| EBITDA | -262.27M |
| EBIT | -318.48M |
| Loss Per Share | -$33.56 |
Full Income StatementBalance Sheet
The company has $70.65 million in cash and $375.10 million in debt, giving a net cash position of -$304.45 million or -$31.32 per share.
| Cash & Cash Equivalents | 70.65M |
| Total Debt | 375.10M |
| Net Cash | -304.45M |
| Net Cash Per Share | -$31.32 |
| Equity (Book Value) | -5.79M |
| Book Value Per Share | -0.60 |
| Working Capital | -145.22M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$263.99 million and capital expenditures -$3.33 million, giving a free cash flow of -$267.32 million.
| Operating Cash Flow | -263.99M |
| Capital Expenditures | -3.33M |
| Free Cash Flow | -267.32M |
| FCF Per Share | -$27.50 |
Full Cash Flow StatementMargins
| Gross Margin | -48.31% |
| Operating Margin | -599.54% |
| Pretax Margin | -551.41% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
bluebird bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -72.23% |
| Shareholder Yield | -72.23% |
| Earnings Yield | -360.71% |
| FCF Yield | -329.29% |
Analyst Forecast
The average price target for bluebird bio is $49.14, which is 488.50% higher than the current price. The consensus rating is "Hold".
| Price Target | $49.14 |
| Price Target Difference | 488.50% |
| Analyst Consensus | Hold |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 66.40% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on December 13, 2024. It was a reverse split with a ratio of 0.05:1.
| Last Split Date | Dec 13, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.05:1 |
Scores
bluebird bio has an Altman Z-Score of -15.68 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -15.68 |
| Piotroski F-Score | 2 |